#BEGIN_DRUGCARD DB08873

# AHFS_Codes:
8:18.40

# ATC_Codes:
J05AE12

# Absorption:
Food increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food.  
Tmax = 2 hours;
Time to steady state, three times a day dosing = 1 day;
Cmax, 400 mg single dose, healthy subject = 557 ng/mL;
AUC ∞, healthy subject = 2020 ng · h/mL;

# Biotransformation:
Hepatically metabolized by the aldo-ketoreductase pathway into inactive metabolites via reduction. To a lesser extent, CYP3A4 and CYP3A5 is also involved in the metabolism of boceprevir (oxidative process).

# Brand_Mixtures:
Not Available

# Brand_Names:
Victrelis

# CAS_Registry_Number:
394730-60-0

# ChEBI_ID:
68621

# Chemical_Formula:
C27H45N5O5

# Chemical_IUPAC_Name:
3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-11 22:45:03 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011.

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antiviral Agents
Protease Inhibitors

# Drug_Interactions:
Alfuzosin	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Atorvastatin	Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored.
Carbamazepine	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Cisapride	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Conivaptan	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Dihydroergotamine	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Drospirenone	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Etravirine	The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown.
Fosphenytoin	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Lomitapide	Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated.
Midazolam	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Phenobarbital	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Phenytoin	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Pimozide	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Ponatinib 	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
Pravastatin	Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored.
Rifampin	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Sirolimus	Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
St. John's Wort	Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
Tacrolimus	Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
Tadalafil	Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.

# Drug_Reference:
22506260	Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10.
22799589	Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.
23140245	Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Boceprevir

# HET_ID:
Not Available

# Half_Life:
Mean plasma half-life = 3.4 hours

# InChI_Identifier:
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1

# InChI_Key:
InChIKey=LHHCSNFAOIFYRV-DOVBMPENSA-N

# Indication:
Treatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08876

# LIMS_Drug_ID:
8884

# Mechanism_Of_Action:
Boceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
519.6767

# Molecular_Weight_Mono:
519.342069575

# Organisms_Affected:
Hepatitis C virus, RSV and other RNA/DNA viruses

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Telaprevir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.

# Predicted_LogP_Hydrophobicity:
1.93

# Predicted_LogS:
-4.3

# Predicted_Water_Solubility:
2.34e-02 g/l

# Primary_Accession_No:
DB08873

# Protein_Binding:
~75%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/victrelis-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-05-12 14:53:55 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Boceprevir

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
23594083	Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA: Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance. ACS Chem Biol. 2013 May 1.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7251

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Hepatitis C virus NS3-4A serine protease

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
B0B3C9

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB08873
